Early Identification of Metabolic Function Derangements Such as Diabetes, Liver, Renal Issues by Respyr Smart Breath Analyzer and Its Validation as a Screening Tool Among Diseased and Healthy Controls
Sponsor: Respyr
Trial Details
| Condition | Diabetes Mellitus, Type 2, Liver Diseases, Kidney Diseases, Lung Diseases, Metabolic Diseases, Healthy Volunteers |
| Status | Completed |
| Participants | 3,000 |
| Est. Completion | 3 Oct 2023 |
| Last Updated | 12 June 2026 |
Primary Outcome
Validation of Smart Breath Analyzer for Screening of Metabolic Disorders
Eligibility Criteria
Inclusion Criteria
Inclusion Criteria: * Participant must either be a completely healthy individual as confirmed by blood examination, or a known case of diabetes, kidney disease, liver disease, and lung disease with relevant diagnostic reports tested within 15 days of participation * All genders and ethnicities * Age 18 to 75 years * Participant who has given informed consent * Participant must be fully vaccinated for COVID-19 * Participant must use the smart breath analyzer at fasting condition; if not fasting, minimum gap of 1 hour after water and 3-4 hours after food Exclusion Criteria: * Individual less than 18 or above 75 years of age * Pregnant and lactating females * Known case of ongoing illness such as Cancer, AIDS, COVID-19, Cough, Fever, TB, Chickenpox, Influenza, Mumps, or Tonsillitis * Individual who has not given informed consent
Trial Sites
Countries
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service